All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Natera Study Links Signatera ctDNA Clearance to Longer Survival Across Four Metastatic Cancers

By Public Technologies
  • Natera will present new Signatera study results at the Society for Immunotherapy of Cancer meeting, Nov. 4-8 in Phoenix.
  • The real-world analysis covered 424 patients receiving first-line immunotherapy across four metastatic cancer types.
  • Patients with two consecutive negative Signatera tests had better long-term survival than other patients, with favorable outcomes across tumor types.
  • Among these molecular responders, stopping immunotherapy early showed no significant survival difference compared with continuing treatment.
  • The findings support further investigation of Signatera to identify patients who may safely stop immunotherapy early.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW562916) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.